Related Experiment Video
Updated: Jul 29, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Fewer Worsening Heart Failure Events With HeartLogic on top of Standard Care: a Propensity-Matched Cohort Analysis
Michelle Feijen1, Monika Beles2, Yan Zhi Tan3
1Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
Insights
The HeartLogic algorithm, used with implantable cardiac defibrillators, reduces worsening heart failure (HF) events and hospitalizations for fluid retention when added to standard care.
Area of Science:
- Cardiology
- Medical Devices
- Digital Health
Background:
- Heart failure (HF) management often involves monitoring for fluid retention.
- The HeartLogic algorithm, integrated with implantable cardiac defibrillators (ICDs), is designed to predict impending fluid retention.
- Prior studies confirm the safety of HeartLogic integration into clinical practice.
Purpose of the Study:
- To evaluate the clinical benefit of the HeartLogic algorithm beyond standard care and device telemonitoring in HF patients.
- To determine if HeartLogic reduces worsening HF events and associated hospitalizations.
Main Methods:
- A multicenter, retrospective, propensity-matched cohort analysis compared HeartLogic to conventional telemonitoring in HF patients with ICDs.
- The primary endpoint was the number of worsening HF events.
- Secondary endpoints included HF hospitalizations and ambulatory visits for diuretic escalation.
Main Results:
- The HeartLogic group experienced fewer worsening HF events (1 vs 2; P=0.004) compared to the control group.
- HF hospitalization days were significantly shorter in the HeartLogic group (5 vs 8 days; P=0.023).
- Ambulatory visits for diuretic escalation were also reduced in the HeartLogic group (1 vs 2; P=0.0001).
Conclusions:
- Integrating the HeartLogic algorithm into HF care pathways improves patient outcomes.
- HeartLogic, when added to standard care and telemonitoring, is associated with a reduction in worsening HF events.
- The algorithm contributes to shorter hospitalizations related to fluid retention in heart failure patients.
Background:
The implantable cardiac defibrillator-based HeartLogic algorithm aims to detect impending fluid retention in patients with heart failure (HF). Studies show that HeartLogic is safe to integrate into clinical practice. The current study investigates whether HeartLogic provides clinical benefit on top of standard care and device telemonitoring in patients with HF.
Methods:
A multicenter, retrospective, propensity-matched cohort analysis was performed in patients with HF and implantable cardiac defibrillators, and it compared HeartLogic to conventional telemonitoring. The primary endpoint was the number of worsening HF events. Hospitalizations and ambulatory visits due to HF were also evaluated.
Results:
Propensity score matching yielded 127 pairs (median age 68 years, 80% male). Worsening HF events occurred more frequently in the control group (2; IQR 0-4) compared to the HeartLogic group (1; IQR 0-3; P = 0.004). The number of HF hospitalization days was higher in controls than in the HeartLogic group (8; IQR 5-12 vs 5; IQR 2-7; P = 0.023), and ambulatory visits for diuretic escalation were more frequent in the control group than in the HeartLogic group (2; IQR 0-3 vs 1; IQR 0-2; P = 0.0001).
Conclusion:
Integrating the HeartLogic algorithm in a well-equipped HF care path on top of standard care is associated with fewer worsening HF events and shorter duration of fluid retention-related hospitalizations.
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure III: Clinical Manifestations
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Heart Failure VI: Adjunct Therapies
Heart Failure II: Pathophysiology